Foundayo vs the Wegovy Pill: Which Daily Weight Loss Tablet Suits You?
Foundayo and the Wegovy pill are both licensed in the UK. Compare weight loss results, daily routine, UK prices and who each tablet suits best.
Key Takeaways
The Wegovy pill shows more weight loss in separate trials (13.6% vs 11.1% at the highest dose tested), but Foundayo has no food or water rules and costs less. They have not been compared head to head.
The Wegovy pill has the stronger weight loss results so far, but Foundayo is easier to take and costs less at every dose step. The two have never been compared in the same trial, so the gap is an estimate, not proof. In practice, the choice often comes down to routine, budget and how much weight you want to lose.
Both are daily tablets, both are GLP-1 medicines, and both are licensed in the UK for weight management. Neither is a different kind of treatment from the injections you may already know. They are alternatives for people who would rather not inject.
Where each pill stands in the UK#
The MHRA has authorised both medicines. The Wegovy tablets have a UK Summary of Product Characteristics (SmPC). For Foundayo, GOV.UK announced in 2026 that the UK had authorised orforglipron (Foundayo) for weight management and type 2 diabetes, the first country in Europe to do so. You can buy both privately from a UK online pharmacy after a clinical assessment.
NHS access is a different matter. NICE has appraised the Wegovy and Mounjaro injections. NHS use of Wegovy is through specialist weight management services (NICE TA875), while Mounjaro is now being rolled out through primary care under NICE TA1026. Both have set BMI and health condition criteria. I am not aware of a NICE appraisal for either pill, so you should not expect an NHS prescription for them. Check the NICE website for any update.
The numbers in one table#
The figures below are from each pill's main trial, at the highest dose tested, in adults with overweight or obesity and no type 2 diabetes. Everyone also had diet and activity advice. The Foundayo figures come from the ATTAIN-1 trial and the Wegovy pill figures from the OASIS 4 trial, both published in the New England Journal of Medicine in 2025 (Wharton et al.).
| Foundayo (orforglipron) | Wegovy pill (oral semaglutide) | |
|---|---|---|
| What it is | Small-molecule GLP-1 medicine | Semaglutide, the same medicine as the Wegovy injection |
| UK tablet strengths | 0.8, 2.5, 5.5, 9, 14.5, 17.2mg | 1.5, 4, 9, 25mg |
| Trial (highest dose tested) | ATTAIN-1, 72 weeks | OASIS 4, 64 weeks |
| Average weight loss (everyone randomised) | 11.1% | 13.6% |
| Average weight loss (if everyone stayed on treatment) | 12.4% | 16.6% |
| Lost at least 10% of body weight | 54.5% | 59.8% |
| Lost at least 15% of body weight | 35.9% | 47.0% |
| Lost at least 20% of body weight | 18.4% | 27.9% |
| Placebo group | About 2% | About 2% |
This is a cross-trial comparison. The trials ran for different lengths, recruited different people and were designed differently. Treat the numbers as a direction, not a verdict.
Trial doses and UK tablet strengths do not always line up. OASIS 4 tested oral semaglutide 25mg a day, which is the top UK Wegovy tablet strength. The Foundayo figures are for the highest dose tested in ATTAIN-1, and the UK tablet strengths are labelled differently, so do not assume the 17.2mg tablet is identical to that trial dose. Your prescriber can explain how the trial doses relate to the licensed strengths.
Why you will see different percentages online#
Trials report weight loss in two ways. One counts everyone who started, including people who stopped the tablets. The other estimates the result if everyone had kept taking them. The second method always gives a bigger number.
That is why you see 13.6% and 16.6% for the same Wegovy pill result. Some pages mix the two methods or quote an earlier trial dose for Foundayo, which makes the pills look further apart or closer together than they are. Compare like with like: 13.6% against 11.1%, or 16.6% against 12.4%.
What this means in kilograms#
Take someone who starts at 100kg (about 15 stone 10lb). At the highest trial doses, the averages suggest a loss of about 13.6kg on the Wegovy pill and about 11.1kg on Foundayo. The difference is roughly 2.5kg, which is under half a stone. Individual results vary a lot, and some people lose far more or far less than the average.
Check your BMI
Not sure where you stand? Work out your BMI in seconds and see whether weight loss treatment could be an option.
Your daily routine on each tablet#
This is the biggest practical difference.
The Wegovy pill must be taken on an empty stomach with a small sip of water. You then wait at least 30 minutes before eating, drinking anything else or taking other medicines. The semaglutide is absorbed in the stomach, and food or extra water gets in the way. If mornings are rushed or you eat early, that wait can be hard to keep to. Our guide on how to take the Wegovy pill covers the routine in detail.
Foundayo has no food or water rules. You can take it at any time of day, with or without a meal. For shift workers, early breakfasters and anyone who forgets things easily, that is a real advantage.
Both pills start low and rise in steps, usually 4 weeks apart. The Wegovy pill has 4 strengths, so you could reach 25mg after about 3 months. Foundayo has 6 strengths, so reaching 17.2mg takes about 5 months if every step goes to plan. Your prescriber sets the pace, and many people stay on a lower dose if it works for them.
What each pill costs per month#
At Totiva, a 30-tablet pack of each strength costs:
| Foundayo | Price | Wegovy Tablets | Price |
|---|---|---|---|
| 0.8mg | £85.88 | 1.5mg | £98.00 |
| 2.5mg | £92.88 | 4mg | £101.00 |
| 5.5mg | £96.88 | 9mg | £116.00 |
| 9mg | £108.88 | 25mg | £165.00 |
| 14.5mg | £138.88 | ||
| 17.2mg | £138.88 |
Foundayo is cheaper at every matched step. For example, the lowest strengths cost £85.88 against £98.00, and the 9mg packs cost £108.88 against £116.00. At the top dose, Foundayo is £26.12 a month cheaper than the Wegovy pill (£138.88 against £165.00).
The Wegovy pill reaches its top dose sooner, but that does not close the gap. If you move up one strength each month and buy one pack a month, the first four months cost roughly £384 for Foundayo and £480 for the Wegovy pill. That assumes no pauses or slower dose steps. There is no subscription, and the consultation is free. You pay only after you are approved.
For comparison, Totiva's Wegovy 2.4mg injection is £188.88 a month and Mounjaro 15mg is £268.88. The pills are cheaper, but the injections have produced more weight loss in their own trials. Our Wegovy pills vs Mounjaro comparison goes into that trade-off.
Weight loss treatments we prescribe
Which pill suits which person#
You want the most weight loss from a tablet. The Wegovy pill has the edge in the trial data, especially for the larger losses (15% or more of body weight). You need to be happy with the empty-stomach routine.
You want the simplest routine. Foundayo. Fewer rules mean fewer missed or mistimed doses, and the best tablet is the one you take consistently.
You are watching the budget. Foundayo costs less at every step, about £26 less a month at the top dose and roughly £96 less over the first four months if you step up monthly. A lower dose of either pill costs less than the top dose, if it works for you.
You are worried about nausea. Neither pill has been shown to be gentler. Both share the usual GLP-1 effects, and slower dose increases help with either one. Do not choose on this point alone.
You are already on an injection. The Wegovy pill contains the same medicine as the Wegovy injection, but the doses and the way it is taken are different. Switching is a prescriber decision. Your prescriber should choose the starting dose, because it will not simply match your injection strength, and should review your weight and appetite after the switch.
You are needle-averse and starting fresh. Either pill is a reasonable first step. If your weight loss stalls at a dose you tolerate, you can ask about stepping up to an injection later.
Safety points for both pills#
The common side effects are nausea, diarrhoea, vomiting, constipation and indigestion. They are usually worst when you start or raise the dose, and they tend to settle. Eating smaller meals and stopping when you feel full helps.
Both medicines are GLP-1 medicines, so the usual GLP-1 warnings apply. These include pancreatitis (severe, persistent stomach pain), gallbladder problems and dehydration. Stop and get medical advice if you get severe stomach pain, yellowing of the skin or eyes, or vomiting you cannot control.
Tell your prescriber before you start if any of these apply, as they may make a GLP-1 tablet unsuitable or mean it needs extra care:
- You or a close relative have had medullary thyroid cancer, or you have multiple endocrine neoplasia type 2 (MEN2).
- You have had pancreatitis before.
- You have type 1 diabetes.
- You take insulin or a sulfonylurea for diabetes. These can cause low blood sugar (hypoglycaemia), so the doses of your diabetes medicines may need adjusting.
- You have, or have had, an eating disorder.
Tell your prescriber about every medicine you take. The Wegovy pill can raise levothyroxine levels, so thyroid patients may need a blood test. Some GLP-1 medicines can also affect how well oral contraceptives are absorbed. Foundayo is a different type of molecule from semaglutide and is newer, so it has its own product information and its own interaction profile. Do not assume that advice for the Wegovy pill applies to Foundayo. Your prescriber should check your medicines against the product information for the tablet you are given.
You should avoid pregnancy while taking either pill. For semaglutide, the Wegovy product information advises stopping at least 2 months before a planned pregnancy. Ask your prescriber to confirm the timing for the tablet you take, particularly Foundayo, and do not stop or restart treatment without their advice.
If you stop, expect appetite to return. In injection trials, many people regained much of the weight within a year of stopping. There is no reason to think the pills are different, so ask about a long-term plan.
You can report any suspected side effect to the MHRA through the Yellow Card scheme.
Questions to ask your prescriber#
- Do I meet the BMI threshold? Most prescribers use BMI 30 or above, or 27 or above with a weight-related condition. For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, the thresholds are lower.
- Will the empty-stomach rule fit my day?
- Which dose do I start on, and how long before each increase?
- Does either pill interact with my current medicines or contraception?
- What is the plan if I miss a dose? (Missed a Wegovy pill dose covers the pill that has a rule.)
- When will you review my progress, and what counts as success?
A good online pharmacy will check your BMI and identity, review your history and offer a clinician review.
If you would like a clinician to help you choose between them, you can start a free weight loss consultation and pay only if you are approved.

Is Wegovy right for you?
From£92.88a month
Answer a few questions and a pharmacist will review whether treatment is suitable. You only pay if you're approved.
- GPhC-registered pharmacists
- Free online consultation
- Discreet, tracked delivery
Frequently asked questions
- 1
Wharton S et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine
- 2
Wharton S et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine
- 3
Novo Nordisk (2026). Wegovy 1.5 mg tablets - Summary of Product Characteristics (SmPC) - (emc). Electronic Medicines Compendium
View source - 4
GOV.UK (2026). UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK
View source - 5
Eli Lilly and Company (2026). FOUNDAYO (orforglipron) tablets, for oral use: US prescribing information. US Food and Drug Administration
View source - 6
NICE (2023). Overview | Semaglutide for managing overweight and obesity | Guidance. NICE Technology Appraisal Guidance
View source - 7
NICE (2024). Overview | Tirzepatide for managing overweight and obesity | Guidance. NICE Technology Appraisal Guidance
View source - 8
Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine
- 9
Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine
- 10
NHS (2023). Overweight and obesity in adults. NHS website
View source
Medical Information: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any treatment.













